Summary: Researchers have identified a key biological mechanism linking the heart and the brain, revealing how a heart attack can directly alter brain function and contribute to depression, anxiety, and cognitive decline. The team found that a highly reactive byproduct, methylglyoxal (MG), spikes in the blood after myocardial infarction and accumulates in brain regions that control mood and memory, driving inflammation and cellular damage.
This finding clarifies a biological pathway behind post‑cardiac psychiatric and cognitive disorders and points to a new therapeutic approach: a peptide designed to bind and neutralize MG before it harms vulnerable brain tissue.
Key Facts
- The heart‑brain axis: Neurological and cognitive problems that emerge after a heart attack can be triggered by a cascade of molecular changes initiated by damage to heart tissue.
- Toxic byproduct accumulation: After myocardial infarction, reduced oxygen, systemic inflammation, and metabolic stress cause levels of methylglyoxal (MG) to surge in the bloodstream and concentrate in brain regions involved in emotion and cognition.
- Psychological and physical risk: Patients recovering from a heart attack experience depression and anxiety at rates up to three times higher than the general population. Those who develop these conditions are up to 2.7 times more likely to suffer a subsequent fatal cardiac event or death.
- Chronic neurological risk: The study shows MG drives localized neuroinflammation and cellular damage in the brain, offering a biological explanation for elevated long‑term dementia risk after heart attacks.
- MG‑trapping peptide: Building on this discovery, the research team developed a peptide therapeutic that selectively binds MG to prevent it from reacting with and damaging neural cells.
- Dual‑system protection: If clinical trials confirm efficacy, the peptide therapy could both preserve brain health and reduce the cardiovascular risks associated with post‑MI depression and anxiety, addressing a significant unmet need in cardiac recovery.
Source: University of Ottawa
New research led by the University of Ottawa reveals how myocardial infarction reshapes brain biology and increases the risk of mood disorders and cognitive impairment.
The work expands the concept of the heart‑brain axis: beyond psychological trauma, structural damage to the heart triggers biochemical changes that reach the brain. Among those changes, methylglyoxal (MG) emerges as a central mediator. MG is a reactive dicarbonyl compound previously studied in metabolic conditions like diabetes; after a heart attack, dying heart tissue and altered systemic metabolism cause MG to rise in the circulation and deposit in brain areas responsible for mood and memory.
Brain inflammation after cardiac events
Following myocardial infarction, the body undergoes oxygen deprivation, inflammation, and metabolic shifts that together drive MG accumulation. The research shows MG and MG‑derived advanced glycation end products (MG‑AGEs) build up in specific brain regions, correlating with increased activation of microglia and macrophages, higher expression of AGE receptors, and elevated inflammatory signaling. These processes coincide with disruption of blood‑brain barrier integrity and reductions in tight junction proteins.
Clinically, the consequences are stark: rates of depression and anxiety are markedly higher among heart attack survivors, and these psychiatric conditions in turn worsen cardiovascular prognosis, increasing the likelihood of another fatal cardiac event.
Charting new territory in brain‑heart interaction
Published in Advanced Science, the study changes how scientists view long‑term outcomes after myocardial infarction. By identifying MG accumulation as a mechanistic link between cardiac injury and brain inflammation, the research provides a testable pathway for interventions aimed at preventing post‑MI cognitive decline and mood disorders.
“Methylglyoxal has been extensively studied in metabolic disease, but its role beyond those settings was less clear,” says senior author Dr. Erik Suuronen, a cardiac surgeon and researcher. “Our prior findings showed MG production from dying heart tissue; this work demonstrates that MG travels to and accumulates in the brain, where it promotes inflammation and cellular damage.”
From discovery to therapy
Identifying MG as a driver of post‑MI neuroinflammation opens therapeutic opportunities. The team has already engineered a peptide that functions like a molecular sponge—recognizing and binding MG to neutralize its reactivity. Preclinical tests will assess whether this approach prevents MG‑related brain injury after a heart attack and whether preserving mental health can in turn lower the risk of subsequent cardiac events.
Dr. Suuronen emphasizes the potential clinical impact: “Protecting the brain after myocardial infarction could also reduce depression and anxiety, which are linked to worse cardiac outcomes. A therapy that addresses both neural and cardiovascular risks would fill an urgent clinical gap.”
Key Questions Answered:
A: The study reveals a physical, toxic pathway: dying heart tissue releases methylglyoxal (MG), which circulates and concentrates in the brain’s emotion and memory centers. There it triggers inflammation and cellular damage that undermines mental health and cognitive function.
A: The heart‑brain axis is bidirectional. MG‑driven brain injury can lead to chronic anxiety and depression, which increase physiological stress on the cardiovascular system, raising the probability of subsequent fatal cardiac events by an estimated factor of up to 2.7.
A: The peptide is designed to selectively bind methylglyoxal, neutralizing its reactivity before it can form harmful adducts with proteins and other cellular components. Acting like a molecular sponge, the peptide aims to prevent MG from infiltrating the central nervous system and causing neuroinflammation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this neurology research news
Author: Paul Logothetis
Source: University of Ottawa
Contact: Paul Logothetis – University of Ottawa
Image: Image credit: Neuroscience News
Original Research: Open access. “Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences” by Ramis Ileri, Xixi Guo, Erik J. Suuronen. Advanced Science. DOI: 10.1002/advs.202522584
Abstract
Methylglyoxal Accumulation is Associated with Brain Inflammation after Myocardial Infarction with Sex and Regional Differences
Patients who suffer myocardial infarction (MI) face an elevated risk of neurological disease and cognitive decline, but the mechanisms linking cardiac injury to brain dysfunction have not been fully clarified. Methylglyoxal (MG), a reactive dicarbonyl compound, is implicated in both cardiovascular and neurological pathology. MG‑derived advanced glycation end products (MG‑AGEs) accumulate in the heart and circulation after MI, making MG a compelling target for studying heart‑brain interactions.
This study reports that MG‑AGEs accumulate in the mouse brain at 6 hours and 7 days post‑MI, with the highest levels in the brainstem and significant presence in the cortex. Male mice showed higher MG‑AGE expression than females in most regions examined. MG accumulation correlated with heightened neuroinflammation—more activated microglia and macrophages—and increased expression of AGE receptors. The tissue also exhibited elevated inflammatory markers (NF‑κB and TNF‑α) and reductions in tight junction proteins associated with blood‑brain barrier integrity.
Taken together, these results describe a novel MG‑mediated mechanism, with sex‑based and regional differences, that likely contributes to heart‑brain communication after MI and identifies MG as a promising therapeutic target to mitigate neurological impairment associated with heart disease.